Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction

Psychosomatics

Volumn 51, Issue 6, 2010, Pages 532-535

  Soskin, David P ^a   Kane, Ari J ^a   Stern, Theodore A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; OXCARBAZEPINE; PHENYTOIN; QUETIAPINE; TOPIRAMATE; VALPROIC ACID;

AGED; ARTICLE; ATAXIA; BIPOLAR DISORDER; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; EPILEPSY; EVENING DOSAGE; FEMALE; HUMAN; MORNING DOSAGE; PATIENT MONITORING;

EID: 78649646281     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1176/appi.psy.51.6.532     Document Type: Article

References (17)

1. Baldessarini R, Henk H, Sklar A, et al: Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008; 59:1175-1183
2. Frye MA, Ketter TA, Leverich GS, et al: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61:9-15
3. American Psychiatric Assoc: Practice Guidelines for the Treatment of Patients With Bipolar Disorder, 2nd Edition. Edited by Hirschfeld R, Bowden C, Gitlin M, et al. Washington, DC, Am Psychiatric Assoc. 2002
4. Suppes T, Dennehy EB, Swann AC, et al: Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder, 2000. J Clin Psychiatry 2002; 63:288-299 (Pubitemid 34456355)
5. Hirschfeld RM, Kasper S: A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004; 7:507-522
6. Vasudev A, Macritchie K, Watson S, et al: Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev; 2008(1):CD005171
7. Juruena MF, Ottoni GL, Machado-Vieira R, et al: Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:94-99
8. Kakkar AK, Rehan HS, Unni KE, et al: Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry 2009; 24:178-182
9. Smith PE: Clinical recommendations for oxcarbazepine. Seizure 2001; 10:87-91
10. Marken PA, Pies RW: Emerging treatments for bipolar disorder: safety and adverse-effect profiles. Ann Pharmacother 2006; 40:276-285
11. May TW, Korn-Merker E, Rambeck B: Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42:1023-1042
12. Corporation NP: Trileptal (package insert), 2003; East Hanover, NJ
13. McKee PJ, Blacklaw J, Forrest G, et al: A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate, and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37:27-32 (Pubitemid 24204577)
14. Barcs G, Walker EB, Elger CE, et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41:1597-1607 (Pubitemid 32002734)
15. Sachdeo RC, Sachdeo SK, Levy RH, et al: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002; 43:691-696
16. Perkins NA, Murphy JE, Malone DC, et al: Performance of drug- drug interaction software for personal digital assistants. Ann Pharmacother 2006; 40:850-855 (Pubitemid 43765002)
17. Barrons R: Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004; 61:380-385 (Pubitemid 39004605)